Jazz Pharmaceuticals Stock Forecast, Price & News

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 1 hold rating and 16 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Jazz Pharmaceuticals stock.
View analyst ratings for Jazz Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Jazz Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Jazz Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Jazz Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Jazz Pharmaceuticals.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) issued its quarterly earnings results on Tuesday, February, 23rd. The specialty pharmaceutical company reported $4.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.58 by $0.42. The specialty pharmaceutical company had revenue of $665.52 million for the quarter, compared to analysts' expectations of $639.83 million. Jazz Pharmaceuticals had a trailing twelve-month return on equity of 20.16% and a net margin of 7.86%. The firm's revenue for the quarter was up 14.4% on a year-over-year basis. During the same period in the prior year, the firm posted $4.42 earnings per share.
View Jazz Pharmaceuticals' earnings history.

Jazz Pharmaceuticals' stock was trading at $108.04 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, JAZZ stock has increased by 56.3% and is now trading at $168.90.
View which stocks have been most impacted by COVID-19.

Jazz Pharmaceuticals issued an update on its FY 2021 After-Hours earnings guidance on Tuesday, February, 23rd. The company provided earnings per share (EPS) guidance of 15.65-16.85 for the period, compared to the Thomson Reuters consensus EPS estimate of $16.78. The company issued revenue guidance of $2.55-2.7 billion, compared to the consensus revenue estimate of $2.56 billion.

18 analysts have issued 1 year price objectives for Jazz Pharmaceuticals' stock. Their forecasts range from $128.00 to $233.00. On average, they anticipate Jazz Pharmaceuticals' share price to reach $186.78 in the next year. This suggests a possible upside of 10.6% from the stock's current price.
View analysts' price targets for Jazz Pharmaceuticals or view top-rated stocks among Wall Street analysts.

60 employees have rated Jazz Pharmaceuticals CEO Bruce C. Cozadd on Glassdoor.com. Bruce C. Cozadd has an approval rating of 92% among Jazz Pharmaceuticals' employees. This puts Bruce C. Cozadd in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Jazz Pharmaceuticals include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Eli Lilly and (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN) and Endo International (ENDP).
View all of JAZZ's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Bank of America (BAC) and Biogen (biib).

Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ."

Jazz Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Retirement Systems of Alabama (0.24%), Cardan Capital Partners LLC (0.04%), Louisiana State Employees Retirement System (0.03%), Centric Wealth Management (0.02%), State of Alaska Department of Revenue (0.02%) and Pacer Advisors Inc. (0.01%). Company insiders that own Jazz Pharmaceuticals stock include Bruce C Cozadd, Catherine A Sohn, Finbar Larkin, Kenneth W O'keefe, Michael Patrick Miller, Patricia Carr, Patrick G Enright, Paul L Berns, Paul Treacy and Seamus Mulligan.
View institutional ownership trends for Jazz Pharmaceuticals.

JAZZ stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, AdvisorNet Financial Inc, Confluence Investment Management LLC, Veriti Management LLC, and Centric Wealth Management. Company insiders that have sold Jazz Pharmaceuticals company stock in the last year include Bruce C Cozadd, Finbar Larkin, Patricia Carr, Patrick G Enright, and Paul L Berns.
View insider buying and selling activity for Jazz Pharmaceuticals or view top insider-selling stocks.

JAZZ stock was acquired by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, TrimTabs Asset Management LLC, Louisiana State Employees Retirement System, Cardan Capital Partners LLC, Pacer Advisors Inc., and Crossmark Global Holdings Inc..
View insider buying and selling activity for Jazz Pharmaceuticals or or view top insider-buying stocks.

Shares of JAZZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of JAZZ stock can currently be purchased for approximately $168.90.

Jazz Pharmaceuticals has a market capitalization of $9.51 billion and generates $2.16 billion in revenue each year. The specialty pharmaceutical company earns $523.37 million in net income (profit) each year or $14.60 on an earnings per share basis.

Jazz Pharmaceuticals employs 1,940 workers across the globe.

Jazz Pharmaceuticals was founded in 2003.

The official website for Jazz Pharmaceuticals is www.jazzpharma.com.

Jazz Pharmaceuticals is headquartered at FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04.

Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The specialty pharmaceutical company can be reached via phone at (531) 634-7800 or via email at [email protected]